In her book, Dementia Reimagined, Tia Powell, MD, director of the Montefiore Albert Einstein Center for Bioethics and professor of psychiatry and bioethics at Albert Einstein College of Medicine, urges us to look at dementia in a different way. [View More]
“We Take Care of Our Own” the Alzheimer’s New Jersey televised benefit that aired in June 2020 on News 12 + has been nominated for a New York Market Emmy Award in the “Community Service” category! This televised [View More]
In a long-awaited decision, the Food and Drug Administration on Monday, June 7, approved Aducanumab as the first new medication for Alzheimer’s disease in nearly two decades and the first to treat the underlying pathology of the disease – not [View More]
Music comes in many forms. There is music in natural sounds like crickets on a hot summer night, waves crashing on the shore and the sound of birds welcoming the morning sun. Music creates mood. The inspiration of a [View More]
It’s been nearly a year since the coronavirus outbreak was declared a pandemic. In that year, almost every aspect of our lives has changed - from the way we work to the way we shop, to the way we spend our leisure...
For several months, Alzheimer’s New Jersey, along with other thought leadership, has been bringing public attention to the crisis of loneliness and isolation in New Jersey’s residential care facilities – a crisis created as an unintended consequence of strict [View More]
This fall, Alzheimer’s New Jersey celebrated Walk to Fight Alzheimer’s® like no other year. Instead of joining together as a community in Point Pleasant Beach, Morristown, Princeton, Jersey City and in Paramus, we connected virtually and brought Walk to [View More]
On October 20, the New Jersey Department of Health amended Executive Directive No 20-026 to expand nursing home visitation for caregivers. The updated directive was intended to bring New Jersey in line with the Centers for Medicare and Medicaid Services’ [View More]
June 7, 2021 update: In a long-awaited decision, the Food and Drug Administration on Monday, June 7, approved Aducanumab as the first new medication for Alzheimer’s disease in nearly two decades and the first to treat the underlying pathology of [View More]
In a recent Alzheimer’s New Jersey blog, I wrote about a new crisis in New Jersey’s residential care facilities. A crisis of isolation and loneliness caused by...
